Who Should Not Take Wegovy?

Many people consider Wegovy because it’s an effective weight management treatment. It helps you feel fuller, lowers appetite and can support steady weight loss when used with diet and activity.

But like any medicine, it isn’t for everyone. Safety, health profile, Wegovy interactions with other medications and pregnancy plans may make it unsuitable.

So this guide explains who Wegovy is for, who should avoid it, and when to pause your treatment plan or stop. And why sharing your full medical history with a clinician is so important for your safety and for avoiding serious side effects of Wegovy.

Who is Wegovy Licensed For?

Wegovy is licensed for adults with obesity (BMI of 30+) or who are overweight (BMI of 27-29.9) with at least one weight-related health problem. This might include high blood pressure, high cholesterol, sleep apnoea, type 2 diabetes or heart disease.

Patients from Black, Asian or other minority ethnic backgrounds can also access Wegovy if they have a BMI of at least 27.

The UK medicines regulator, the MHRA, has only licensed it for use in adult patients (aged 18 and above), alongside a healthy diet and exercise.

Who Cannot Use Wegovy?

“Wegovy isn’t suitable for patients who are pregnant or breastfeeding, who have a [personal or family] history of some thyroid cancers, who have pancreatitis or who might be on certain medications,” explains Abdal Alvi, Chief Clinical Officer at Simple Online Pharmacy.

The following patients may have to seek alternatives to Wegovy for managing their weight.

Anyone Allergic to Semaglutide

You shouldn’t use Wegovy if you’ve ever had an allergic reaction to semaglutide, the medication’s active ingredient. Or if you’ve had a reaction to any ingredient in the injection.

Patients With a History of Thyroid Cancer

If you or a close family member has had a rare thyroid cancer, tell your clinician. Speak to a doctor if you’ve had either medullary thyroid cancer (MTC). Or if you’ve had a condition called multiple endocrine neoplasia syndrome type 2 (MEN2).

Studies in rodents have found a link between GLP-1 receptor activation and thyroid tumours. While it hasn’t been found in humans, the link cannot be ruled out. So, as a precaution, clinicians do not recommend Wegovy if you have a history of these conditions.

Anyone With a History of Pancreatitis

Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist. These medications work by slowing down the rate food leaves your stomach (called “delayed gastric emptying). That’s why common side effects are stomach related (e.g. vomiting, constipation and diarrhoea).

Some patients taking GLP-1 medicines have reported acute pancreatitis on the treatment. So, if you’ve had pancreatitis before, you shouldn’t use Wegovy as you’re at an increased risk of developing it.

Pancreatitis symptoms include sudden, sharp or burning pain in the upper abdomen. This often radiates to the back and pain may worsen after eating. You may feel this alongside persistent nausea (with or without vomiting).

Other symptoms include:

• Fatty stools (pale, bulky, foul-smelling stools due to poor fat digestion)
• Jaundice (yellowing of the skin or eyes)
• Back pain

If you think you may have pancreatitis, seek urgent medical attention.

People on Some Medication (Including Other GLP-1s)

There aren’t any direct interactions between Wegovy and other drugs. However, it can affect the absorption of some medications. For example antibiotics, warfarin (blood thinners) or antipsychotics.

You should not combine Wegovy with other GLP-1 medicines (Mounjaro, Saxenda or Ozempic). Using two incretin-based drugs together can raise side-effect risks.

Patients using insulin are not eligible for Wegovy.

Patients with Certain Health Conditions

As well as pancreatitis and thyroid cancer, Wegovy may not be recommended in patients with other conditions. For example, patients with any active cancer and/or patients having chemotherapy or radiotherapy.

It’s not recommended for those with severe damage to the kidneys or liver, severe heart failure or unstable diabetic retinopathy (an eye condition caused by diabetes).

Your prescriber will weigh the risks and benefits if any of these apply to you.

Pregnant or Breastfeeding Patients

You should not use Wegovy (or other GLP-1 weight loss drugs) while pregnant or breastfeeding.

The UK’s medicines regulator (MHRA) advises women to use effective contraception while on medication.

If you are planning a pregnancy, stop Wegovy for at least two months before trying. This will ensure the medication is completely out of our system. If you become pregnant while taking Wegovy, speak to your prescriber and GP for advice on what to do next.

Wegovy and Pregnancy: Why is the Medication Unsuitable?

Wegovy is unsuitable during pregnancy because there isn’t enough information on whether it could cause the baby harm.

Breastfeeding is also not recommended while on Wegovy because a risk to the baby can’t be ruled out. Again, if you could become pregnant, use effective contraception while using Wegovy.

Can You Take Wegovy with No Gallbladder?

Having no gallbladder (after a cholecystectomy) is not a formal contraindication to Wegovy. Many people without a gallbladder can still use GLP-1 medicines.

However, some studies have found a link between GLP-1 treatments and a higher risk of gallbladder or biliary problems (like gallstones and inflammation).

Rapid weight loss can also raise gallstone risk. If you’ve had gallbladder disease before, or you get right-upper tummy pain, fever or yellowing of the skin/eyes, get checked quickly.

Practical takeaways if you don’t have a gallbladder:

• It’s not an automatic no, but you should discuss your history with your clinician.
• Watch for biliary symptoms (stones can form in bile ducts even after gallbladder removal).
• Report new stomach pain, persistent nausea/vomiting, fever or jaundice urgently.
• Keep hydrated and follow the dose-increase plan slowly to limit stomach side effects.

When to Stop or Pause Wegovy

Stop and get medical advice if any of the following happen, as it might suggest Wegovy is not suitable:

• If you are or you’re planning to conceive soon, stop and speak to your clinician.
• If you have symptoms that suggest acute pancreatitis. E.g. sudden severe upper abdominal pain, often radiating to the back, with persistent nausea with or without vomiting). Don’t restart if it’s confirmed pancreatitis.
• Signs of gallbladder or biliary problems (right-upper tummy pain, fever, jaundice).
• Severe dehydration from ongoing vomiting or diarrhoea. This can affect your kidneys. You may need fluids and a dose review.
• A serious allergic reaction (swelling of face/lips/tongue, trouble breathing, widespread rash). If this happens, seek urgent medical attention.

Why You Need to Tell a Provider Your Medical History

Wegovy can interact with your health in several ways. Patients with some conditions, or who take some medications, need extra care. For example, if you’re using diabetes medication, have kidney problems, or are taking blood thinners.

So it’s important you tell your provider your medical history. If you’re buying weight loss injections online, fill out your assessment honestly. Don’t leave out any relevant information. This can reduce the risk of experiencing potential side effects that are more serious.

“The key thing here is that patients should try to obtain the medications from regulated providers,” Abdal says. “Being injectable, prescription-only medications, patients need to take where they’re obtaining them from very seriously.”

“If you go to a provider and they don’t have an assessment, or they don’t have a regulated healthcare professional, patients should be suspicious of that,” he adds.

Key Takeaways

• Who Wegovy Is For: Adults with BMI 30+, (or 27+ for patients with a weight-related condition or BAME background). Use alongside diet and activity.
• Who Shouldn’t Use It: It’s not suitable for those who are pregnant or breastfeeding or allergic to Wegovy. Or if you have a personal/family history of MTC or MEN2, you may have to use other methods to lose weight.
• Medicine Interactions: Don’t mix Wegovy with other GLP-1 weight loss medications (e.g. Mounjaro, Saxenda, Ozempic). Tell your clinician your full health history and medicines. Especially insulin, sulfonylureas, warfarin, kidney problems, diabetic eye disease, or mental health history.
• Safety Warnings: Seek urgent help for pancreatitis (severe upper tummy pain, often radiating to the back, persistent nausea with or without vomiting). Or gallbladder problems (upper right tummy pain, fever or jaundice).
• When to Pause or Stop: Stop or pause if side effects are severe, or you’re planning a pregnancy. Talk to your healthcare provider first.

References

and, M. (2025). Women on ‘skinny jabs’ must use effective contraception, MHRA urges in latest guidance. [online] GOV.UK. Available at: https://www.gov.uk/government/news/women-on-skinny-jabs-must-use-effective-contraception-mhra-urges-in-latest-guidance (Accessed: 20 September 2025).

He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, Y., Xu, L., Li, W. & Zhang, H., 2022. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Internal Medicine [online]. 182(5), pp.513–519. Available from: https://doi.org/10.1001/jamainternmed.2022.0338 (Accessed: 20 September 2025).

Kolding, L., Henriksen, J.N., Sædder, E.A., Ovesen, P.G. & Pedersen, L.H., 2025. Pregnancy outcomes after semaglutide exposure. Basic & Clinical Pharmacology & Toxicology [online]. 136(4), e70021. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11906903/ (Accessed: 20 September 2025).

and, M. (2025). If you take a GLP-1 medicine and have been hospitalised by acute pancreatitis, the Yellow Card Biobank wants to hear from you. [online] GOV.UK. Available at: https://www.gov.uk/government/news/if-you-take-a-glp-1-medicine-and-have-been-hospitalised-by-acute-pancreatitis-the-yellow-card-biobank-wants-to-hear-from-you (Accessed: 27 October 2025).

‌Christophe, Hosn, O.A., Ghzayel, L. and Mourad, M. (2025). Exploring Connections Between Weight‐Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database. Endocrinology Diabetes & Metabolism, [online] 8(2). doi: https://doi.org/10.1002/edm2.70038 (Accessed: 27 October 2025).

Authorship